TheraCryf Plc

1. 02 Oct 26
   Australian partner to progress Ox-1 Phase 1 trial

   Australian partner appointed to progress Ox-1 towards Phase 1 trial

   RNS 9803056 ↗
2. 28 Sep 26
   Final Results

   Final Results for the year ended 31 March 2026

   RNS 9792613 ↗
3. 20 Aug 26
   Proposed Placing & Subscription to raise £1.05m

   Proposed Placing and Subscription to raise £1.05 million

   RNS 9732839 ↗
4. 14 May 26
   Positive Ox-1 tox data in addiction programme

   Positive top line data from first toxicology species in lead Ox-1 addiction programme

   RNS 9567507 ↗
5. 21 Apr 26
   Investor Webinar

   TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that Dr Huw Jones, Chief Executive Officer and Dr Helen Kuhlman, Chief Operating Officer, will host an investor...

   RNS 9529336 ↗
6. 20 Apr 26
   Successful GMP Manufacture Advances Ox-1 to Clinic

   Lead Asset Ox-1 Advances Towards Clinic With Successful GMP Manufacture For Human Use

   RNS 9526926 ↗
7. 16 Apr 26
   New Manufacturing Process Patent for Ox-1

   New Manufacturing Process Patent Extends Exclusivity for Lead Asset Ox-1

   RNS 9522416 ↗
8. 14 Apr 26
   Non-Binding Proposal to Acquire TheraCryf’s Assets

   Non-Binding Indicative Proposal to Acquire TheraCryf's Lead Neuropsychiatry Assets Received

   RNS 9517942 ↗
9. 23 Mar 26
   Ox-1 Programme Advances to Final Toxicology Study

   Lead Ox-1 Programme Advances to Final Toxicology Studies Before Human Phase 1 Clinical Study

   RNS 9485558 ↗
10. 26 Jan 26
    Ox-1 Addiction Programme Update

    Best-in-class Ox-1 asset continues to be de-risked ahead of clinical readiness

    RNS 9385540 ↗
11. 05 Jan 26
    Key Ox-1 milestone & notice of investor webinar

    Ox-1 addiction programme advances closer to clinical readiness on achievement of key milestone

    RNS 9332339 ↗
12. 18 Dec 25
    Potential of Preclinical Program in Mental Fatigue

    · Chronic fatigue treatment market worth US$1.2 billion in 2024, rising to c.US$2.3bn by 20331

    RNS 9305037 ↗
13. 03 Dec 25
    Half-year Results

    Class-leading addiction programme on target to be clinic ready in 2026

    RNS 9271803 ↗
14. 26 Nov 25
    Marking Addiction Awareness Week

    Alderley Park, 26 November 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, is supporting Addiction Awareness Week.

    RNS 9257305 ↗
15. 03 Nov 25
    Ox-1 Programme Achieves Manufacturing Milestone

    Scale up of drug quantity achieved ahead of schedule

    RNS 9207509 ↗
16. 16 Oct 25
    Holding(s) in Company 30 % crossed / offer

    TR-1: Standard form for notification of major holdings

    RNS 9176171 ↗
17. 16 Oct 25
    Director/PDMR Shareholding Director buys30 % crossed / offer

    Alderley Park, UK - 16 October 2025: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, announces that Northern Standard Limited, a company that Non-Executive Director, Ed Wardle, has a 49 per cent interest...

    RNS 9176170 ↗
18. 10 Oct 25
    World Mental Health Day & Q4 Conference Schedule

    Marking World Mental Health Day and Q4 Conference Schedule Update

    RNS 9162330 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.